Skip to main content

Research Repository

Advanced Search

Antigenicity and immunogenicity of differentially glycosylated HCV E2 envelope proteins expressed in mammalian and insect cells

Urbanowicz, Richard A.; Wang, Ruixue; Schiel, John E.; Keck, Zhen-yong; Kerzic, Melissa C.; Lau, Patrick; Rangarajan, Sneha; Garagusi, Kyle J.; Tan, Lei; Guest, Johnathan D.; Ball, Jonathan K.; Pierce, Brian G.; Mariuzza, Roy A.; Foung, Steven K. H.; Fuerst, Thomas R.

Antigenicity and immunogenicity of differentially glycosylated HCV E2 envelope proteins expressed in mammalian and insect cells Thumbnail


Authors

Richard A. Urbanowicz

Ruixue Wang

John E. Schiel

Zhen-yong Keck

Melissa C. Kerzic

Patrick Lau

Sneha Rangarajan

Kyle J. Garagusi

Lei Tan

Johnathan D. Guest

JONATHAN BALL jonathan.ball@nottingham.ac.uk
Professor of Molecular Virology

Brian G. Pierce

Roy A. Mariuzza

Steven K. H. Foung

Thomas R. Fuerst



Abstract

Development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global health challenge. Cumulative evidence supports the importance of antibodies targeting the HCV E2 envelope glycoprotein to facilitate viral clearance. However, a significant challenge for a B cell-based vaccine is focusing the immune response on conserved E2 epitopes capable of eliciting neutralizing antibodies not associated with viral escape. We hypothesized that glycosylation might influence the antigenicity and immunogenicity of E2. Accordingly, we performed head-to-head molecular, antigenic and immunogenic comparisons of soluble E2 (sE2) produced in (i) mammalian (HEK293) cells, which confer mostly complex and high mannose type glycans; and (ii) insect (Sf9) cells, which impart mainly paucimannose type glycans. Mass spectrometry demonstrated that all 11 predicted N-glycosylation sites were utilized in both HEK293- and Sf9-derived sE2, but that N-glycans in insect sE2 were on average smaller and less complex. Both proteins bound CD81 and were recognized by conformation-dependent antibodies. Mouse immunogenicity studies revealed that similar polyclonal antibody responses were generated against antigenic domains A–E of E2. Although neutralizing antibody titers showed that Sf9-derived sE2 induced moderately stronger responses than HEK293-derived sE2 against the homologous HCV H77c isolate, the two proteins elicited comparable neutralization titers against heterologous isolates. Given that global alteration of HCV E2 glycosylation by expression in different hosts did not appreciably affect antigenicity or overall immunogenicity, a more productive approach to increasing the antibody response to neutralizing epitopes may be complete deletion, rather than just modification, of specific N-glycans proximal to these epitopes.

Citation

Urbanowicz, R. A., Wang, R., Schiel, J. E., Keck, Z., Kerzic, M. C., Lau, P., …Fuerst, T. R. (2019). Antigenicity and immunogenicity of differentially glycosylated HCV E2 envelope proteins expressed in mammalian and insect cells. Journal of Virology, 93(7), https://doi.org/10.1128/jvi.01403-18

Journal Article Type Article
Acceptance Date Dec 20, 2018
Online Publication Date Jan 16, 2019
Publication Date Jan 16, 2019
Deposit Date Jan 25, 2019
Publicly Available Date Jan 25, 2019
Journal Journal of Virology
Print ISSN 0022-538X
Electronic ISSN 1098-5514
Publisher American Society for Microbiology
Peer Reviewed Peer Reviewed
Volume 93
Issue 7
DOI https://doi.org/10.1128/jvi.01403-18
Keywords Immunology; Insect Science; Microbiology; Virology
Public URL https://nottingham-repository.worktribe.com/output/1496837
Publisher URL https://jvi.asm.org/content/early/2019/01/10/JVI.01403-18